Literature DB >> 9494007

Rectal cancer following colectomy and ileorectal anastomosis for familial adenomatous polyposis.

D C Jenner1, S Levitt.   

Abstract

BACKGROUND: Familial adenomatous polyposis (FAP) has historically been treated by colectomy and ileorectal anastomosis (IRA). Preservation of the rectum allows the subsequent development of cancer in the rectum. The risk of rectal cancer following ileorectal anastomosis in the Australian population has not been published to date.
METHODS: An audit of the Familial Adenomatous Polyposis Registry of Western Australia was undertaken to assess patients who had undergone colectomy and ileorectal anastomosis. Fifty-five patients ranging in age from 13 to 65 years were studied.
RESULTS: Seven patients (13%) developed cancer of the rectum with a median follow-up of 10 years (range: 1-31 years). Median interval to diagnosis of carcinoma of the rectum following colectomy and IRA was 10 years. All patients who developed cancer in the retained rectum had rectal polyps. Colon cancer was present in the initial colectomy specimen in 13 patients (of these, five patients developed rectal cancer). Flat polyps were noted in five patients. Four patients with flat polyps developed cancer of the rectum.
CONCLUSIONS: Total colectomy and IRA should be considered as part 1 of a staged procedure in the patient with FAP. With the exception of the patient with no evidence of rectal polyps, completion proctectomy should be undertaken within 10 years of the initial colectomy.

Entities:  

Mesh:

Year:  1998        PMID: 9494007     DOI: 10.1111/j.1445-2197.1998.tb04724.x

Source DB:  PubMed          Journal:  Aust N Z J Surg        ISSN: 0004-8682


  2 in total

1.  Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human.

Authors:  Paola Alberici; Emma de Pater; Joana Cardoso; Mieke Bevelander; Lia Molenaar; Jos Jonkers; Riccardo Fodde
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.

Authors:  Carol A Burke; Evelien Dekker; N Jewel Samadder; Elena Stoffel; Alfred Cohen
Journal:  BMC Gastroenterol       Date:  2016-08-02       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.